Segment disclosures

Company overview

ANAPTYSBIO, INC.

Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.

Revenue · Reported segment facts

4 dimension combinations 25 retained observations 12 reported periods

Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.

Biopharma Company

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=anab:BiopharmaCompanyMember
PeriodValueUnitFiledEvidence
2026-01-01 – 2026-03-310 USD20260512Open filing evidence
2025-01-01 – 2025-12-310 USD20260303Open filing evidence
2025-01-01 – 2025-03-310 USD20260512Open filing evidence
2024-01-01 – 2024-12-310 USD20260303Open filing evidence
2023-01-01 – 2023-12-310 USD20260303Open filing evidence

Research And Development Segment

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=anab:ResearchAndDevelopmentSegmentMember
PeriodValueUnitFiledEvidence
2025-07-01 – 2025-09-3076320000 USD20251104Open filing evidence
2025-01-01 – 2025-09-30126354000 USD20251104Open filing evidence
2025-04-01 – 2025-06-3022263000 USD20250806Open filing evidence
2025-01-01 – 2025-06-3050034000 USD20250806Open filing evidence
2025-01-01 – 2025-03-3127771000 USD20250505Open filing evidence
2024-01-01 – 2024-12-3191280000 USD20250227Open filing evidence
2024-07-01 – 2024-09-3030017000 USD20251104Open filing evidence
2024-01-01 – 2024-09-3048167000 USD20251104Open filing evidence
2024-04-01 – 2024-06-3010971000 USD20250806Open filing evidence
2024-01-01 – 2024-06-3018150000 USD20250806Open filing evidence
2024-01-01 – 2024-03-317179000 USD20250505Open filing evidence
2023-01-01 – 2023-12-3117157000 USD20250227Open filing evidence
2022-01-01 – 2022-12-3110287000 USD20250227Open filing evidence

Royalty Management Company

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=anab:RoyaltyManagementCompanyMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-3030274000 USD20261112Open filing evidence
2026-01-01 – 2026-03-3125556000 USD20260512Open filing evidence
2025-01-01 – 2025-12-31234603000 USD20260303Open filing evidence
2025-01-01 – 2025-03-3127771000 USD20260512Open filing evidence
2024-01-01 – 2024-12-3191280000 USD20260303Open filing evidence
2023-01-01 – 2023-12-3117157000 USD20260303Open filing evidence

Prior To Spin Off · Royalty Management Company

Statement Operating Activities Segment · Statement Business Segments

Source dimensions us-gaap:StatementOperatingActivitiesSegmentAxis=anab:PriorToSpinOffMember;us-gaap:StatementBusinessSegmentsAxis=anab:RoyaltyManagementCompanyMember
PeriodValueUnitFiledEvidence
2025-07-01 – 2025-09-3076320000 USD20261112Open filing evidence